Author + information
- Received February 25, 2010
- Revision received April 21, 2010
- Accepted April 26, 2010
- Published online July 1, 2010.
- Kaori Inoue, MD⁎,
- Sadako Motoyama, MD, PhD⁎,⁎ (, )
- Masayoshi Sarai, MD, PhD⁎,
- Takahisa Sato, MD, PhD⁎,
- Hiroto Harigaya, MD⁎,
- Tomonori Hara, MD⁎,
- Yoshihiro Sanda, MD†,
- Hirofumi Anno, MD, PhD†,
- Takeshi Kondo, MD, PhD‡,
- Nathan D. Wong, PhD§,
- Jagat Narula, MD, PhD§ and
- Yukio Ozaki, MD, PhD⁎
- ↵⁎Reprint requests and correspondence:
Dr. Sadako Motoyama, Department of Cardiology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan
Objectives This study sought to assess, by serial computed tomography angiography (CTA), the effect of statin treatment on coronary plaque morphology.
Background In addition to the assessment of luminal stenosis, CTA also allows characterization of plaque morphology. Large, positively remodeled plaques with large necrotic cores have been reported as indicators of plaque instability.
Methods CTA was performed in 32 patients (26 men, ages 64.3 ± 8.5 years). Of these, 24 received fluvastatin after the baseline study; 8 subjects who refused statin treatment were followed as the control subjects. Serial imaging was performed after a median interval of 12 months. All vessels were examined in every subject, and a 10-mm-long segment was identified for comparison before and after intervention. Total plaque volume, low attenuation plaque (LAP) volume, lumen volume, and remodeling index were calculated.
Results In the statin-treated patients, the total plaque volume (92.3 ± 37.7 vs. 76.4 ± 26.5 mm3, p < 0.01) and LAP volume (4.9 ± 7.8 vs. 1.3 ± 2.3 mm3, p = 0.01) were significantly reduced over time; however, there was no change in the lumen volume (63.9 ± 25.3 vs. 65.2 ± 26.2 mm3, p = 0.59). On the other hand, no change was observed in the CTA characteristics in the control subjects, including total plaque volume (94.4 ± 21.2 vs. 98.4 ± 28.6 mm3, p = 0.48), LAP volume (2.1 ± 3.0 vs. 2.3 ± 3.6 mm3, p = 0.91), and lumen volume (80.5 ± 20.7 vs. 75.0 ± 16.3 mm3, p = 0.26). The plaque volume change (−15.9 ± 22.2 vs. 4.0 ± 14.0 mm3, p = 0.01) and LAP volume change (−3.7 ± 7.0 vs. 0.2 ± 1.5 mm3, p < 0.01) were significantly greater in the statin than the control group. The lumen volume (1.3 ± 15.6 vs. −5.5 ± 13.1 mm3, p = 0.24) and remodeling index (−2.4 ± 6.8% vs. −0.3 ± 6.5%, p = 0.53) did not show the significant differences between the 2 groups. The decrease in the plaque volume was due to reduction in the LAP volume (R = 0.83, p < 0.01), and was not related to any changes in the lumen volume (R = 0.21, p = 0.24).
Conclusions This preliminary study suggests that serial CTA evaluation of coronary plaques allows for the assessment of interval change in the plaque morphology. Statin treatment results in decreases in the plaque and necrotic core volume. The features known to be associated with plaque instability.
Drs. Narula and Ozaki contributed equally to the manuscript. Pim J. de Feyter, MD, served as Guest Editor for this article.
- Received February 25, 2010.
- Revision received April 21, 2010.
- Accepted April 26, 2010.
- American College of Cardiology Foundation